K. Bochinski

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

K. Bhalla, H. Kantarjian, J. Cortes, 2006, The New England journal of medicine.

of early complete and major cytogenetic responses positive chronic myelogenous leukemia: high incidence - chromosome Imatinib mesylate therapy in newly diagnosed patients with Philadelphia

G. Garcia-Manero, J. Cortes, M. Talpaz, 2013 .

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies.

A. Lockhart, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[A case of accessory tracheal bronchus].

K. Bochinski, W. Dworak, J. Dybicki, 1958, Schweizerische Zeitschrift fur Tuberkulose und Pneumonologie. Revue suisse de la tuberculose et de pneumonologie. Rivista svizzera della tubercolosi e della pneumonologia.

[2 Cases of Castelman's tumor of the lung].

J. Nowakowski, K. Bochinski, J. Dybicki, 1966, Gruzlica i choroby pluc; tuberculosis et pneumonologia.

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.